News

Hershey's 2025 Financial Overview: Strong Growth Signals for 2026

Hershey's 2025 Financial Overview: Strong Growth Signals for 2026

Hershey's Strong Financial Performance in 2025

The Hershey Company (NYSE: HSY) has recently shared its impressive net sales and earnings results for the fourth quarter and full-year of 2025. This comprehensive report emphasizes the company's resilience and strategic initiatives that promise to fuel further growth. President and Chief Executive Officer, Kirk Tanner, expressed confidence in the company’s direction, highlighting the team’s adeptness in navigating through tough market conditions.

Highlights from the Fourth Quarter of 2025

During the fourth quarter, Hershey achieved consolidated net sales of $3,091.0 million, reflecting a notable increase of 7.0% compared to the previous year. The organic, constant currency net sales saw a growth of 5.7%. Despite a decrease in reported net income to $320.0 million, adapting strategies led to adjusted earnings per share of $1.71. This comparison against the backdrop of market volatility underscores the effectiveness of Hershey's pricing strategies and product positioning.

Fourth-Quarter Financial Performance Snapshot

  • Consolidated net sales: $3,091.0 million (+7.0%)
  • Organic net sales growth: 5.7%
  • Reported net income: $320.0 million (-59.9%)
  • Adjusted earnings per share: $1.71 (-36.4%)

Full-Year Financial Results Overview

For the entirety of 2025, Hershey reported consolidated net sales of $11,692.6 million, marking a growth of 4.4% from the prior year. This increase was partially fueled by acquisitions contributing a 0.5 point benefit while currency fluctuations presented a challenge, reflecting an impact of 0.3 points on the sales growth.

2025 Full-Year Performance Details

  • Consolidated net sales: $11,692.6 million (+4.4%)
  • Organic, constant currency sales: +4.2%
  • Reported net income: $883.3 million (-60.3%)
  • Adjusted earnings per share: $6.31 (-32.7%)

2026 Financial Outlook

Looking ahead, Hershey's projections for 2026 are optimistic, expecting reported net sales growth of 4% to 5%. This growth is anticipated to be propelled by strategic pricing, enhanced product innovation, and aggressive marketing campaigns. The company also foresees adjusted earnings per share ranging between $8.20 and $8.52, indicating a solid increase when compared to the previous year’s performance.

2026 Projections Overview

  • Net sales growth: 4% to 5%
  • Expected adjusted earnings per share: $8.20 to $8.52 (+30% to 35% year-over-year)
  • Reported earnings per share: $7.77 to $8.19 (+79% to 89% increase)

Sector Performance and Strategic Actions

The company’s strong focus on sector performance is evident from its initiatives undertaken in the North America Confectionery and Salty Snacks markets. The integration of businesses, including the acquisition of LesserEvil, LLC, has played a crucial role in boosting sales and expanding market share.

Key Sector Developments

  • North America Confectionery net sales reached $2,478.5 million, highlighting a 5.3% increase.
  • Salty Snacks segment reported remarkable growth with net sales totaling $357.0 million, a significant increase of 28.0%.
  • Margins faced pressure due to challenges such as rising commodity costs and tariffs, yet marketing strategies helped maintain growth momentum.

Conclusion

In summary, The Hershey Company not only demonstrated strong revenue growth in 2025 but has also set a promising trajectory for 2026. The strategic deployments in marketing, innovation, and acquisitions emphasize its commitment to enhancing shareholder value, despite market fluctuations. Hershey's performance reflects its ability to adapt and thrive in a complex environment, making it a compelling choice for investors looking at future growth.

Frequently Asked Questions

1. What were Hershey’s net sales for 2025?

Hershey reported consolidated net sales of $11,692.6 million for the year 2025.

2. How much did Hershey's earnings per share change year-over-year?

The adjusted earnings per share for Hershey decreased by 32.7% to $6.31 in 2025.

3. What is Hershey's growth outlook for 2026?

Hershey expects reported net sales growth to range between 4% and 5% for 2026.

4. What are the expected earnings per share for Hershey in 2026?

The expected adjusted earnings per share for 2026 is projected to be between $8.20 and $8.52.

5. What strategies is Hershey using to enhance sales?

Hershey is focusing on net price realization, increased innovation, and significant marketing efforts to support demand.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

TORRAS Stands Tall with iPhone 18 Pro Cases

Updated Category News Views 191

TORRAS Shines in Magnetic Stand Case Evaluation In the whirlwind of smartphone accessories, where the battle lines are drawn between protection and functionality, TORRAS has emerged victorious with its magnetic stand cases for the iPhone 18 Pro and its beefier brother, the iPhone 18 Pro Max. Expert Consumers—a trusted name in product evaluations—has given TORRAS the...

Continue Reading
Darden Faces Class Action Over Reimbursement Failures

Updated Category News Views 125

Class Action Puts Darden Restaurants in Legal Hot Seat Darden Restaurants, Inc. is staring down the barrel of a lawsuit that's as fiery as a grill on a Saturday night rush. The legal cavalry from Blumenthal Nordrehaug Bhowmik De Blouw LLP has stormed in with a class action complaint, aiming dead center at Darden for allegedly breaching the California Labor Code. In plain...

Continue Reading
Survivors Secure $800M Settlement with NY Archdiocese

Updated Category News Views 143

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

Continue Reading
World Young Scientist Summit 2026 in Wenzhou Kicks Off

Updated Category News Views 109

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Continue Reading
Apalutamide Boosts Outlook for Prostate Cancer Treatment

Updated Category News Views 69

Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...

Continue Reading
Lilly's Sofe-M Shakes Up Ovarian Cancer Treatment

Updated Category News Views 253

Ovarian Cancer Treatment Sees a New Challenger Alright, folks, Eli Lilly (NYSE:LLY) is stepping up with their latest findings in ovarian cancer treatment, and it's got plenty of people in a buzz. They've dropped new data for their investigational drug, Sofetabart mipitecan, or 'Sofe-M' for short, which targets this unrelenting disease with a punch that’s hard to ignore....

Continue Reading
DIRECTV Bags New NHL Deals: Stakes for Sports Fans

Updated Category News Views 209

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

Continue Reading
Axon Body 5: A Leap Forward in AI for Public Safety

Updated Category News Views 261

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...

Continue Reading
What to Expect: Your First Therapy Session Insights

Updated Category News Views 136

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Continue Reading
Bio-Thera's New Data: A Game Changer for NSCLC?

Updated Category News Views 214

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...

Continue Reading

Top 5 Most Recently Viewed Articles

QHSLab’s Strategic Growth: NSF Invitation Fuels Innovation

Updated Category News Views 235

QHSLab Celebrates a New Milestone in Drug Delivery Technology QHSLab Inc. (OTCQB: USAQ), known for its pioneering approaches in digital healthcare solutions, has been granted a prestigious opportunity by the National Science Foundation (NSF). The invitation to submit a full application for their groundbreaking AIR-GUIDDE (Airway Instantaneous Regional Guided Interface for...

Continue Reading
Guns N' Roses' Iconic Track Chosen for Gundam Film Theme

Updated Category News Views 126

Guns N' Roses' Iconic Track Chosen for Gundam Film Theme Today, Bandai Namco Filmworks has revealed an exciting collaboration: the celebrated rock ballad "Sweet Child O' Mine" by Guns N' Roses will grace the ending credits of the much-anticipated film MOBILE SUIT GUNDAM HATHAWAY The Sorcery of Nymph Circe. As fans eagerly await the release, the emotional depth of the song...

Continue Reading
Arko Plans Major Shift by Divesting Convenience Store Chain

Updated Category News Views 112

Arko's Strategic Shift in the Convenience Store Market Arko, based in Richmond, Virginia, is in the spotlight as it explores the possibility of selling off its convenience store operations. This deal could be worth around $2 billion and signifies a notable pivot in the company's approach amidst challenges in the retail industry. As discussions unfold, it appears Arko is...

Continue Reading
Galaxy Therapeutics Welcomes Dr. Michael Alexander as CMO

Updated Category News Views 509

Galaxy Therapeutics Strengthens Leadership with New CMO In a notable step forward, Galaxy Therapeutics has announced the appointment of Dr. Michael Alexander as Chief Medical Officer. This move aligns perfectly with the company’s objectives of enhancing its clinical and scientific teams as they work towards the development and eventual commercialization of their...

Continue Reading
Exploring Global Heritage Initiatives and Their Impact

Updated Category News Views 307

World Heritage initiatives roared through the scene, pushing for a blend of culture and dialogue that few could ignore. Nations weren’t just hanging on; they were diving headfirst into programs like the Global Development Initiative (GDI) and the Global Security Initiative (GSI). These aren't just talk shops; they're part of a broader movement to enhance human...

Continue Reading